KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Income from Continuing Operations rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $251.5 million for Q3 2025, which was up 373.29% from -$92.0 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $251.5 million during Q3 2025, with a 5-year trough of -$364.7 million in Q2 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Income from Continuing Operations had a median value of $126.4 million in 2023 and averaged $113.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 641.83% in 2022, then spiked by 1,116.53% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Income from Continuing Operations stood at -$32.3 million in 2021, then crashed by 641.83% to -$240.0 million in 2022, then spiked by 139.43% to $94.6 million in 2023, then soared by 102.01% to $191.1 million in 2024, then increased by 16.77% to $251.5 million in 2025.
  • Its Income from Continuing Operations was $251.5 million in Q3 2025, compared to -$92.0 million in Q2 2025 and $191.1 million in Q4 2024.